Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study

Background: Olaparib maintenance therapy has shown efficacy and tolerability in patients with platinum-sensitive, high-grade serous recurrent ovarian cancer (HSROC) with BRCA1/2 mutation (BRCAm). Our aim was to present real-world experience with olaparib in Korea. Method: We included HSROC patients...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Med
Hlavní autoři: Paik, E Sun, Lee, Yong Jae, Lee, Jung-Yun, Shin, Wonkyo, Park, Sang-Yoon, Kim, Se Ik, Kim, Jae-Weon, Choi, Chel Hun, Kim, Byoung-Gie
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6912318/
https://ncbi.nlm.nih.gov/pubmed/31717415
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8111920
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky